Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
Unity Biotechnology Inc (UBX)UBX
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based out of last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2024: UBX (1-star) is a SELL. SELL since 3 days. Profits (-18.02%). Updated daily EoD!
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: SELL |
Profit: -64.31% | Upturn Advisory Performance  2 | Avg. Invested days: 19 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 09/18/2024 |
Type: Stock | Today’s Advisory: SELL |
Profit: -64.31% | Avg. Invested days: 19 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 09/18/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.92M USD |
Price to earnings Ratio - | 1Y Target Price 6.67 |
Dividends yield (FY) - | Basic EPS (TTM) -1.92 |
Volume (30-day avg) 43751 | Beta 0.83 |
52 Weeks Range 1.22 - 2.54 | Updated Date 09/18/2024 |
Company Size Small-Cap Stock | Market Capitalization 23.92M USD | Price to earnings Ratio - | 1Y Target Price 6.67 |
Dividends yield (FY) - | Basic EPS (TTM) -1.92 | Volume (30-day avg) 43751 | Beta 0.83 |
52 Weeks Range 1.22 - 2.54 | Updated Date 09/18/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.08% | Return on Equity (TTM) -87.32% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 11598623 | Price to Sales(TTM) 6.54 |
Enterprise Value to Revenue 29.79 | Enterprise Value to EBITDA -0.23 |
Shares Outstanding 16847600 | Shares Floating 14655915 |
Percent Insiders 1.31 | Percent Institutions 20.52 |
Trailing PE - | Forward PE - | Enterprise Value 11598623 | Price to Sales(TTM) 6.54 |
Enterprise Value to Revenue 29.79 | Enterprise Value to EBITDA -0.23 | Shares Outstanding 16847600 | Shares Floating 14655915 |
Percent Insiders 1.31 | Percent Institutions 20.52 |
Analyst Ratings
Rating 4.5 | Target Price 7.67 | Buy 1 |
Strong Buy 1 | Hold - | Sell - |
Strong Sell - |
Rating 4.5 | Target Price 7.67 | Buy 1 | Strong Buy 1 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Unity Biotechnology Inc.: A Detailed Overview
Company Profile:
History and Background:
Unity Biotechnology Inc. was founded in 2011 by a team of scientists and entrepreneurs with a vision to develop drugs to prevent, treat, and reverse age-related diseases by targeting senescent cells.
Core Business Areas:
- Developing senolytic drugs that selectively remove senescent cells from the body.
- Advancing a portfolio of product candidates in various stages of development for age-related diseases like osteoarthritis, chronic kidney disease, and neurodegenerative disorders.
Leadership Team and Corporate Structure:
- CEO: Keith Leonard
- President and COO: Jamie Danan
- Chief Scientific Officer: Nathaniel David, Ph.D.
- Executive Vice President, Clinical Development: Anish Bhatnagar, M.D.
The company has a board of directors composed of industry experts and scientists.
Top Products and Market Share:
Top Products:
- UBX0101: In Phase 2b clinical trial for the treatment of osteoarthritis of the knee.
- UBX1325: In Phase 1b clinical trial for the treatment of CKD.
- UBX1967: In preclinical development for the treatment of neurodegenerative disorders.
Market Share:
Unity Biotechnology is still in the early stages of development and does not currently have any approved products. Therefore, it does not have a current market share.
Competitors:
- Cleara Biotech
- Oisín Biotechnologies
- Elevian
- Ichor Therapeutics
Product Performance and Market Reception:
The company's lead product, UBX0101, has shown promising results in early clinical trials for osteoarthritis of the knee. However, it is still too early to say how it will perform in the market.
Total Addressable Market:
The global market for senolytics is estimated to be worth $10.3 billion by 2027. This market is expected to grow at a CAGR of 23.1% from 2022 to 2027.
Financial Performance:
Unity Biotechnology is a pre-revenue company, so it does not have any revenue or earnings. The company is currently funded by venture capital and grants.
Recent Acquisitions (last 3 years):
Unity Biotechnology has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
Based on an AI-based rating system, Unity Biotechnology Inc. receives a rating of 7 out of 10. This rating is based on the company's strong science, promising early clinical results, and significant market potential. However, the company is still in the early stages of development and faces significant risks.
Sources and Disclaimers:
This analysis is based on publicly available information from the following sources:
- Unity Biotechnology Inc. website
- SEC filings
- News articles
- Industry reports
This information is intended for educational purposes only and should not be considered investment advice. Investing in early-stage companies like Unity Biotechnology comes with significant risks, and you should conduct your own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Unity Biotechnology Inc
| Exchange | NASDAQ | Headquaters | South San Francisco, CA, United States |
| IPO Launch date | 2018-05-03 | CEO & Director | Dr. Anirvan Ghosh Ph.D. |
| Sector | Healthcare | Website | https://unitybiotechnology.com |
| Industry | Biotechnology | Full time employees | 19 |
| Headquaters | South San Francisco, CA, United States | ||
| CEO & Director | Dr. Anirvan Ghosh Ph.D. | ||
| Website | https://unitybiotechnology.com | ||
| Website | https://unitybiotechnology.com | ||
| Full time employees | 19 |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.